Therapy News and Research

RSS

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

UCB and Immunomedics Inc. announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEM™, showed the clinical efficacy of epratuzumab in patients with SLE.

16 Jun 2010

SOA provides clarity regarding law's consequences on existing health insurance plans, benefits

With the approaching national implementation of The Mental Health Parity and Addiction Equity Act on July 1, 2010, members of the Society of Actuaries are providing clarity regarding the law's potential unintended consequences on consumers' existing health insurance plans and benefits. While the law is intended to provide non-discriminatory mental health coverage, members of the SOA are helping consumers and large and small employers understand what effects the law will have on current health plan offerings, and what individuals can do to help avoid higher out-of-pocket costs.

16 Jun 2010

Report on treatment trends in systemic lupus erythematosus

BioTrends is pleased to announce the upcoming publication of a new syndicated report, TreatmentTrends®: Systemic Lupus Erythematosus (SLE). This report will provide a comprehensive market overview of current and future treatment trends in SLE based on a primary research study fielded with 102 rheumatologists in the U.S. during the first week in June.

16 Jun 2010

Physicians play stronger role in ensuring asthma patients don't waver in taking drugs: Researchers

Armed with the right information, physicians can play a stronger role in ensuring asthma patients don't waver in taking drugs proven to prevent asthma attacks, according to researchers at Henry Ford Hospital in Detroit.

16 Jun 2010

Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma

Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fourth scheduled safety analysis and recommended that the trial continue per the protocol.

16 Jun 2010

KCI's Prevena Incision Management System receives FDA clearance

Kinetic Concepts, Inc. announced today it has received 510(k) clearance from the Food and Drug Administration for the Prevena Incision Management System, a negative pressure wound therapy product designed for management of surgically closed incisions. KCI estimates more than three million procedures are performed each year worldwide that could benefit from treatment with the Prevena System, representing a potential global opportunity greater than $1 billion.

16 Jun 2010

Many Huntington's disease patients suffer from weight loss, sleeping problems

An aggregating protein causes many of the symptoms of Huntington's disease, an incurable and frequently fatal brain disorder. Mosaic winner Ahmad Aziz discovered that the abnormal protein also aggregates in the hypothalamus, the part of the brain that regulates the autonomic nervous system and the endocrine system.

16 Jun 2010

New online smoking-cessation study launched

Fred Hutchinson Cancer Research Center announced today that it is launching a new online study to help people quit smoking. The study, called WebQuit, is enrolling adult smokers nationwide. Participation is free to eligible individuals.

16 Jun 2010

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.

16 Jun 2010

Dutch researcher investigates causes and consequences of insomnia

The brains of older adults with chronic sleep problems look different from those of adults who have enjoyed enough sleep. Yet the older adults function well despite their lack of sleep. They switch to a continuous form of mild stress, as a result of which they sometimes even perform better than contemporaries who enjoy a good night's sleep says Dutch researcher Ellemarije Altena.

16 Jun 2010

European market for continuous glucose monitoring to reach $52M in 2016

The continuous glucose monitoring (CGM) market is in its development stage. The primary factor leading to the growth of the (CGM) market in Europe is the need for an easy-to-use and patient-friendly glucose-monitoring device. The traditional method of monitoring glucose was difficult and inconvenient for patients. The CGM method is not only hassle-free, but also gives a better diagnosis of diabetes.

16 Jun 2010

Exercise helps patients recover shoulder movement after breast cancer surgery

An active 72-year-old woman, Claire Mitchell had always enjoyed cooking. However, after breast cancer surgery she found that she had less freedom of movement and reaching jars on high shelves became quite painful. Her plight is common.

16 Jun 2010

Diabetes associated with increased risk of cancer

A new consensus statement of experts assembled by the American Diabetes Association and the American Cancer Society reviews emerging evidence that suggests cancer incidence is associated with diabetes as well as certain diabetes risk factors and treatments. The new report reviews the state of science concerning the association between diabetes and cancer incidence/prognosis; risk factors common to both diseases; possible biologic links between diabetes and cancer risk; and whether diabetes treatments influence the risk of cancer or cancer prognosis.

16 Jun 2010

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

16 Jun 2010

Newly published research examines association between CKD and CYP24

Cytochroma today announced the publication of new data from studies in a preclinical model indicating that chronic kidney disease is associated with markedly increased expression of the vitamin D catabolic enzyme, CYP24, which contributes to vitamin D insufficiency and resistance to vitamin D therapy. Parallel analysis of kidney biopsies obtained from CKD patients confirmed abnormal CYP24 expression in human disease as well.

16 Jun 2010

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.

16 Jun 2010

European Commission grants Orphan Medicinal Product Designation for QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that the European Commission has granted Orphan Medicinal Product Designation for QPI-1002 (also referred to as "I5NP") for the prophylaxis of delayed graft function in kidney transplant patients.

16 Jun 2010

UT Southwestern head and neck cancer surgeons perform area's first transoral robotic surgery

Head and neck cancer surgeons at UT Southwestern Medical Center performed the area's first transoral robotic surgery (TORS), a recently approved minimally invasive no-scar procedure to remove tumors in the throat.

16 Jun 2010

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

Through a unanimous decision, the Florida Advisory Council on Radiation Protection has endorsed Target Safely, the American Society for Radiation Oncology's (ASTRO) patient protection plan.

16 Jun 2010

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

QLT Inc. today announced that final results from the Novartis-sponsored Phase IIIb DENALI study were presented on June 8, 2010 during the World Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to wet age-related macular degeneration (all lesion types).

16 Jun 2010

Therapy News and Research

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

SOA provides clarity regarding law's consequences on existing health insurance plans, benefits

Report on treatment trends in systemic lupus erythematosus

Physicians play stronger role in ensuring asthma patients don't waver in taking drugs: Researchers

Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma

KCI's Prevena Incision Management System receives FDA clearance

Many Huntington's disease patients suffer from weight loss, sleeping problems

New online smoking-cessation study launched

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Dutch researcher investigates causes and consequences of insomnia

European market for continuous glucose monitoring to reach $52M in 2016

Exercise helps patients recover shoulder movement after breast cancer surgery

Diabetes associated with increased risk of cancer

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

Newly published research examines association between CKD and CYP24

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

European Commission grants Orphan Medicinal Product Designation for QPI-1002

UT Southwestern head and neck cancer surgeons perform area's first transoral robotic surgery

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News